The ever-evolving landscape of management strategies and therapeutics for the treatment of multiple sclerosis (MS) requires that clinicians stay abreast of not only novel therapies but also advances that could change the face of patient care. Using biomarkers in managing MS can aid clinicians in selecting therapies and accurately predicting the disease course